PRKN and Parkinson disease: ABL1 is present in its activated form in Parkinson’s disease (PD) patients as well as in preclinical models of the disease; furthermore, ABL1 has been reported to phosphorylate α-synuclein at Y39 and the E3 ligase Parkin, both of which are genetic risk factors for PD (Ko et al., 2010; Imam et al., 2011; Schlatterer et al., 2011; Brahmachari et al., 2016; Karim et al., 2020).